| Name | Title | Contact Details |
|---|
Betz Nursing Home is a Auburn, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Teva Neuroscience is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Kansas City, MO. To find more information about Teva Neuroscience, please visit www.tevaneuro.com
Since its beginning in 2007 as a technical staffing and business solutions group in Annapolis, Md., Syndicus has evolved into a highly respected technical staffing and consulting solutions group that provides talent and solutions for three focus areas: Health Information Technology, Life Sciences Solutions and Technology Services. We pride ourselves in partnering with top subject matter experts who ensure candidates, consultants and solutions meet clients' specialized needs. In 2012, Syndicus achieved both a full national accreditation with the Management Services Organization Accreditation Program (MSOAP) from the Electronic Healthcare Network Accreditation Commission (EHNAC) and the MSO State Designation from the Maryland Health Care Commission (MHCC). The two certifications enable Syndicus and its electronic health records (EHR) hosted solutions provider eCast Corporation to continue working with Maryland healthcare providers on EHR adoption efforts – and subsequent achievement of Meaningful Use.
Catholic Charities CYO is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Catholic Charities CYO is based in San Francisco, CA. You can find more information on Catholic Charities CYO at www.cccyo.org
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.